Type 1 diabetes (Juvenile Diabetes) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Type 1 diabetes (Juvenile Diabetes) - Pipeline Review, H1 2016

Type 1 diabetes (Juvenile Diabetes) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Type 1 diabetes (Juvenile Diabetes) - Pipeline Review, H1 2016
Published Jun 08, 2016
631 pages — Published Jun 08, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2016, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes)
- The report reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Type 1 Diabetes (Juvenile Diabetes) therapeutics and enlists all their major and minor projects
- The report assesses Type 1 Diabetes (Juvenile Diabetes) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players an

  
Source:
Document ID
GMDHC7967IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Introduction21
Table of Contents231
  List of Tables274
  List of Figures311
  Global Markets Direct Report Coverage321
Type 1 diabetes (Juvenile Diabetes) Overview331
Therapeutics Development342
  Pipeline Products for Type 1 diabetes (Juvenile Diabetes) Overview341
  Pipeline Products for Type 1 diabetes (Juvenile Diabetes) Comparative Analysis351
Type 1 diabetes (Juvenile Diabetes) Therapeutics under Development by Companies369
Type 1 diabetes (Juvenile Diabetes) Therapeutics under Investigation by Universities/Institutes452
Type 1 diabetes (Juvenile Diabetes) Pipeline Products Glance474
  Late Stage Products471
  Clinical Stage Products481
  Early Stage Products491
  Unknown Stage Products501
Type 1 diabetes (Juvenile Diabetes) Products under Development by Companies5113
Type 1 diabetes (Juvenile Diabetes) Products under Investigation by Universities/Institutes642
Type 1 diabetes (Juvenile Diabetes) Companies Involved in Therapeutics Development66104
  AbGenomics International, Inc.661
  Adocia671
  AiCuris GmbH &Co. KG681
  Alteogen Inc.691
  Amarantus Bioscience Holdings, Inc.701
  Ambrx, Inc.711
  AntriaBio, Inc.721
  Aphios Corporation731
  APT Therapeutics, Inc.741
  Araim Pharmaceuticals, Inc.751
  Argos Therapeutics, Inc.761
  Artery Therapeutics, Inc.771
  Astellas Pharma Inc.781
  AstraZeneca Plc791
  Athersys, Inc.801
  Axxam SpA811
  Beta-Cell NV821
  Biocon Limited831
  Biodel Inc.841
  Biogenomics Limited851
  BioLineRx, Ltd.861
  BioLingus AG871
  BioTherapeutics Inc.881
  Boehringer Ingelheim GmbH891
  Caladrius Biosciences, Inc.901
  Carlina Technologies SAS911
  Cellectis S.A.921
  Compugen Ltd.931
  Daewoong Pharmaceutical Co., Ltd.941
  Dance Biopharm Inc.951
  Diabetology (Products) Ltd961
  DiaMedica Inc.971
  Diamyd Medical AB981
  Diasome Pharmaceuticals, Inc.991
  Dompe Farmaceutici S.p.A.1001
  Effimune S.A.1011
  Eli Lilly and Company1021
  enGene, Inc1031
  Ensol Biosciences Inc.1041
  EpiVax, Inc.1051
  Evotec AG1061
  F. Hoffmann-La Roche Ltd.1071
  Fate Therapeutics, Inc.1081
  Generex Biotechnology Corporation1091
  GeNeuro SA1101
  Geropharm1111
  Gilead Sciences, Inc.1121
  GlaxoSmithKline Plc1131
  Grifols, S.A.1141
  Heptares Therapeutics Limited1151
  Iltoo Pharma1161
  Innopharmax Inc.1171
  IntelliCell BioSciences Inc.1181
  Intrexon Corporation1191
  Islet Sciences, Inc.1201
  Johnson &Johnson1211
  Kadimastem Ltd.1221
  Kamada Ltd.1231
  Kasiak Research Private Limited1241
  Kineta, Inc.1251
  Kissei Pharmaceutical Co., Ltd.1261
  Lexicon Pharmaceuticals, Inc.1271
  Ligand Pharmaceuticals, Inc.1281
  Lonestar Heart, Inc.1291
  MacroGenics, Inc.1301
  Medestea Research &Production S.p.A.1311
  MedImmune, LLC1321
  Merck &Co., Inc.1331
  Meridigen Biotech Co., Ltd.1341
  MidaSol Therapeutics LP1351
  Mitsubishi Tanabe Pharma Corporation1361
  NOD Pharmaceuticals, Inc.1371
  Novo Nordisk A/S1381
  Noxxon Pharma AG1391
  Oramed Pharmaceuticals, Inc.1401
  Orgenesis, Inc.1411
  Paras Biopharmaceuticals Finland Oy1421
  Parvus Therapeutics, Inc.1431
  Pathfinder Cell Therapy, Inc.1441
  Pfizer Inc.1451
  PharmaCyte Biotech, Inc.1461
  PharmaIN Corporation1471
  Progen Pharmaceuticals Limited1481
  Prometheon Pharma, LLC1491
  Purzer Pharmaceutical Co., Ltd.1501
  RedHill Biopharma Ltd.1511
  REGiMMUNE Corporation1521
  Sanofi1531
  SEKRIS Biomedical, Inc.1541
  Selecta Biosciences, Inc.1551
  Sevion Therapeutics, Inc.1561
  Strongbridge Biopharma plc1571
  Therapix Biosciences Ltd1581
  Thermalin Diabetes, LLC1591
  Toleranzia AB1601
  Transgene Biotek Limited1611
  UCB S.A.1621
  Uni-Bio Science Group Ltd.1631
  United Therapeutics Corporation1641
  ViaCyte, Inc.1651
  Visionary Pharmaceuticals, Inc.1661
  XL-protein GmbH1671
  XOMA Corporation1681
  Zensun (Shanghai) Sci &Tech Co., Ltd.1691
Type 1 diabetes (Juvenile Diabetes) Therapeutics Assessment17015
  Assessment by Monotherapy Products1701
  Assessment by Combination Products1711
  Assessment by Target1725
  Assessment by Mechanism of Action1774
  Assessment by Route of Administration1812
  Assessment by Molecule Type1832
Drug Profiles185447
  (clarithromycin + clofazimine + rifabutin) - Drug Profile1853
    Product Description1851
    Mechanism of Action1851
    R&D Progress1853
  (cyclosporine + lansoprazole) - Drug Profile1881
    Product Description1881
    Mechanism of Action1881
    R&D Progress1881
  (Glucagon-Like Peptide-1 + insulin human) - Drug Profile1891
    Product Description1891
    Mechanism of Action1891
    R&D Progress1891
  (insulin aspart + insulin aspart protamine) - Drug Profile1901
    Product Description1901
    Mechanism of Action1901
    R&D Progress1901
  (insulin aspart + insulin degludec) - Drug Profile1912
    Product Description1911
    Mechanism of Action1911
    R&D Progress1912
  (insulin glargine + insulin glulisine) - Drug Profile1931
    Product Description1931
    Mechanism of Action1931
    R&D Progress1931
  (insulin glargine + insulin lispro) - Drug Profile1941
    Product Description1941
    Mechanism of Action1941
    R&D Progress1941
  (insulin human + pramlintide acetate) - Drug Profile1951
    Product Description1951
    Mechanism of Action1951
    R&D Progress1951
  (insulin lispro + insulin lispro protamine) - Drug Profile1961
    Product Description1961
    Mechanism of Action1961
    R&D Progress1961
  2-AMD - Drug Profile1971
    Product Description1971
    Mechanism of Action1971
    R&D Progress1971
  4548G-05 - Drug Profile1981
    Product Description1981
    Mechanism of Action1981
    R&D Progress1981
  AB-101 - Drug Profile1991
    Product Description1991
    Mechanism of Action1991
    R&D Progress1991
  AbGn-168H - Drug Profile2002
    Product Description2001
    Mechanism of Action2001
    R&D Progress2002
  ABS-11 - Drug Profile2021
    Product Description2021
    Mechanism of Action2021
    R&D Progress2021
  AGS-010 - Drug Profile2032
    Product Description2031
    Mechanism of Action2031
    R&D Progress2032
  AIC-284 - Drug Profile2051
    Product Description2051
    Mechanism of Action2051
    R&D Progress2051
  AKS-091 - Drug Profile2061
    Product Description2061
    Mechanism of Action2061
    R&D Progress2061
  albiglutide - Drug Profile2073
    Product Description2071
    Mechanism of Action2071
    R&D Progress2073
  aldesleukin - Drug Profile2101
    Product Description2101
    Mechanism of Action2101
    R&D Progress2101
  aldesleukin - Drug Profile2111
    Product Description2111
    Mechanism of Action2111
    R&D Progress2111
  ALM - Drug Profile2121
    Product Description2121
    Mechanism of Action2121
    R&D Progress2121
  alpha-1 proteinase inhibitor (human) - Drug Profile2131
    Product Description2131
    Mechanism of Action2131
    R&D Progress2131
  alpha-1 proteinase inhibitor (human) - Drug Profile2142
    Product Description2141
    Mechanism of Action2141
    R&D Progress2142
  AMRS-001 - Drug Profile2163
    Product Description2161
    Mechanism of Action2161
    R&D Progress2163
  Antibody for Neurodegenerative Diseases and Diabetes - Drug Profile2191
    Product Description2191
    Mechanism of Action2191
    R&D Progress2191
  APH-0907 - Drug Profile2201
    Product Description2201
    Mechanism of Action2201
    R&D Progress2201
  BetaGRAFT - Drug Profile2211
    Product Description2211
    Mechanism of Action2211
    R&D Progress2211
  BIOD-531 - Drug Profile2222
    Product Description2221
    Mechanism of Action2221
    R&D Progress2222
  Biologic to Activate Glutamic Acid Decarboxylase and IL-10 for Type 1 diabetes - Drug Profile2241
    Product Description2241
    Mechanism of Action2241
    R&D Progress2241
  Biologic to Target Insulin Receptor and IL-10 for Type 1 diabetes - Drug Profile2251
    Product Description2251
    Mechanism of Action2251

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Type 1 diabetes (Juvenile Diabetes) - Pipeline Review, H1 2016" Jun 08, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Type-1-diabetes-Juvenile-Diabetes-Pipeline-Review-H1-2016-2088-15893>
  
APA:
Global Markets Direct - Market Research. (2016). Type 1 diabetes (Juvenile Diabetes) - Pipeline Review, H1 2016 Jun 08, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Type-1-diabetes-Juvenile-Diabetes-Pipeline-Review-H1-2016-2088-15893>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.